Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04655157
Title Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Jason J. Luke, MD
Indications

melanoma

Therapies

Encorafenib + Ipilimumab + Nivolumab

Binimetinib + Encorafenib + Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST